for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Open Orphan PLC

ORPH.L

Latest Trade

23.29GBp

Change

0.29(+1.26%)

Volume

1,046,125

Today's Range

23.00

 - 

24.00

52 Week Range

4.50

 - 

32.45

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
23.00
Open
23.25
Volume
1,046,125
3M AVG Volume
128.71
Today's High
24.00
Today's Low
23.00
52 Week High
32.45
52 Week Low
4.50
Shares Out (MIL)
730.81
Market Cap (MIL)
158.65
Forward P/E
59.28
Dividend (Yield %)
--

Next Event

Open Orphan PLC Annual Shareholders Meeting

Latest Developments

More

Open Orphan Says Collaboration With Hic-Vac And Wellcome Trust

Open Orphan Announces New 2.5 Mln Stg Influenza Challenge Study Contract Win

Open Orphan Plc Gets New 2-Yr Contract With A Tier 1 German Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Open Orphan PLC

Open Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.

Industry

Business Services

Contact Info

Queen Mary BioEnterprises

Innovation Centre, 42 New Road,

E1 2AX

United Kingdom

+44.28.90737900

http://www.vennlifesciences.com/

Executive Leadership

Cathal Friel

Executive Chairman of the Board

Trevor Philips

Chief Executive Officer

Leo Toole

Chief Financial Officer, Executive Director

Gracielle Anna Maria Beijerbacht-Schutjens

Executive Director

Cornelis Groen

Executive Director

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (EUR)

2017

-0.030

2018

-0.030

2019

-0.030

2020(E)

0.008
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.94
Price To Book (MRQ)
5.90
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.36
LT Debt To Equity (MRQ)
8.41
Return on Investment (TTM)
-55.98
Return on Equity (TTM)
-43.59

Latest News

Latest News

Britain moves closer to COVID-19 vaccine trials that infect volunteers

"Human challenge" trials of potential COVID-19 vaccines, where volunteers are deliberately infected with the disease, could become a reality after a British biotech firm said it was in advanced talks with the government to create and provide strains of the virus.

BRIEF-Open Orphan Signs Contract For COVID-19 Vaccine Trial

* CONTRACT WITH CODAGENIX FOR PHASE I TRIAL OF A SINGLE-DOSE, INTRANASAL SARS-COV-2 VACCINE CANDIDATE IN 48 HEALTHY YOUNG ADULTS

BRIEF-Open Orphan Signs 3 New Contracts With Third Parties

* OPEN ORPHAN PLC - SIGNED 3 NEW CONTRACTS WITH THIRD PARTIES Source text for Eikon: Further company coverage:

BRIEF-Open Orphan Says Strategic Review Underway To Seek To Monetise 49% Stake In Imutex

* OPEN ORPHAN PLC - STRATEGIC REVIEW IS UNDERWAY IN ORDER TO SEEK TO MONETISE 49% STAKE IN IMUTEX

BRIEF-Open Orphan Says Signed Contract With A Vaccine Developer And Pharmaceutical Companies

* OPEN ORPHAN PLC - SIGNED A MAJOR CONTRACT WITH A LEADING VACCINE DEVELOPER AND TOP PHARMACEUTICAL COMPANIES Source text for Eikon: Further company coverage:

BRIEF-Open Orphan Announces Launch Of Covid-19 Antibody Testing

* OPEN ORPHAN - LAUNCH OF HVIVO COVID CLEAR TEST, CO'S ANTIBODY TESTING SERVICE, FOLLOWING SUCCESSFUL COMPLETION OF INSTALLATION, TESTING AND TRAINING Source text for Eikon: Further company coverage:

BRIEF-Open Orphan Says Fundraising Raised About £12 Mln Through Placing

* FUNDRAISING HAS RAISED ABOUT £12 MILLION THROUGH PLACING OF 109.5 MILLION NEW ORDINARY SHARES

BRIEF-Open Orphan Announces Proposed Fundraising To Raise Up To £12 Mln

* OPEN ORPHAN PLC - PROPOSED FUNDRAISING TO RAISE UP TO £12 MILLION

BRIEF-Open Orphan Announce Conditional Offer For Subscription Of New Shares

* OPEN ORPHAN - ANNOUNCE CONDITIONAL OFFER FOR SUBSCRIPTION VIA PRIMARYBID OF NEW ORDINARY SHARES AT ISSUE PRICE OF 11P/PER NEW SHARE

BRIEF-Open Orphan PLC Updates On Antibody Test And Share Price Movement

* CONFIRMS MOSAIQ COVID-19 ANTIBODY MICROARRAY MACHINE ON SITE AT HVIVO'S LABORATORY IN EAST LONDON

BRIEF-Open Orphan Says Trevor Phillips Standing Down As CEO

* OPEN ORPHAN PLC - MAJOR NEW CONTRACT AND DIRECTORATE CHANGE

BRIEF-Open Orphan Unit Starts Testing Of Anti-Viral For COVID-19 Treatment

* OPEN ORPHAN SAYS ITS LONDON-BASED UNIT HVIVO COMMENCED TESTING OF ANTI-VIRAL FOR TREATING COVID-19 ON BEHALF OF ITS CLIENT NEARMEDIC INTERNATIONAL LTD Source text for Eikon: Further company coverage:

BRIEF-Open Orphan Announces Positive Results Of A Phase IIB Challenge Study Of Flu-V 004 In NPJ Vaccines

* POSITIVE RESULTS OF A PHASE IIB CHALLENGE STUDY OF FLU-V 004 (STUDY 004, NCT03180801) IN NPJ VACCINES Source text for Eikon: Further company coverage:

BRIEF-Open Orphan Says Commenced Development Of Commercial Human Coronavirus Challenge Study Model

* OPEN ORPHAN - COMMENCED DEVELOPMENT OF COMMERCIAL HUMAN CORONAVIRUS CHALLENGE STUDY MODEL

BRIEF-Open Orphan Plc Says New hVIVO Contract Signed With A European Biotech Company

* OPEN ORPHAN PLC SAYS NEW HVIVO CONTRACT SIGNED WITH A EUROPEAN BIOTECH COMPANY

BRIEF-Open Orphan Announces Appointment Of Leo Toole As Chief Financial Officer

* ANNOUNCES APPOINTMENT TO BOARD OF LEO TOOLE AS CHIEF FINANCIAL OFFICER

BRIEF-Open Orphan Appoints Leo Toole As CFO

* OPEN ORPHAN PLC - APPOINTMENT OF LEO TOOLE TO ROLE OF GROUP CHIEF FINANCIAL OFFICER WITH IMMEDIATE EFFECT Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up